Pixantrone in patients with relapsed/refractory diffuse large B‐cell lymphoma: A real‐life, retrospective, multicenter trial on behalf of the “RTL” (Regional Tuscan Lymphoma network)-Reference-Cited by-同舟云学术

Pixantrone in patients with relapsed/refractory diffuse large B‐cell lymphoma: A real‐life, retrospective, multicenter trial on behalf of the “RTL” (Regional Tuscan Lymphoma network)

Published:2022-01-30 Issue:5 Volume:108 Page:383-390
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Cencini Emanuele¹^ORCID,Mecacci Bianca¹,Rocco Melania²,Innocenti Fabio²,Ghio Francesco³,Puccini Benedetta⁴,Della Seta Roberta⁵,Simonetti Federico⁶,Mannelli Lara⁷,Cuccaro Annarosa⁸,Bocchia Monica¹,Fabbri Alberto¹

Affiliation:

1. Unit of Hematology Azienda Ospedaliera Universitaria Senese and University of Siena Siena Italy

2. SOC Ematologia Clinica e Oncoematologia Firenze Italy

3. Unit of Hematology Azienda Ospedaliera Universitaria Pisana and University of Pisa Pisa Italy

4. Lymphoma Unit Hematology Department Careggi Hospital and University of Florence Firenze Italy

5. Hematology Unit Ospedale di Carrara Lido di Camaiore Italy

6. UOC Ematologia Aziendale Ospedale Versilia Lido di Camaiore Italy

7. SOS Oncoematologia Ospedale S. Stefano Prato Italy

8. UOC Ematologia Aziendale Azienda USL Toscana Nordovest Spedali Riuniti Livorno Italy

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13745

Reference33 articles.

1. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

3. MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients

4. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma

5. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pixantrone as a novel MCM2 inhibitor for ovarian cancer treatment;European Journal of Pharmacology;2024-09

2. Long‐term efficacy in patients with relapsed/refractory diffuse large B‐cell lymphoma achieving a complete response with pixantrone;European Journal of Haematology;2023-05-10

3. Pixantrone/rituximab;Reactions Weekly;2022-08-06

4. Pixantrone in patients with relapsed/refractory diffuse large B‐cell lymphoma: A real‐life, retrospective, multicenter trial on behalf of the “RTL” (Regional TUSCAN Lymphoma Network)—Authors' reply to Morris and colleagues;European Journal of Haematology;2022-07-28

5. Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma;European Journal of Haematology;2022-07-26